Companies Should Market All Centrally Approved Medicines In All EU Markets, Says The Netherlands
The Dutch health ministry says companies should market new and innovative medicines with a centralized marketing authorization in all EU markets and is calling for EU-wide discussions.
You may also be interested in...
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.